Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Diclofenac and DFMO for Chemoprevention in Skin Cancer
NCT04091022Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Jan 2021
- Primary completion
- Dec 2025
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-melanoma skin cancer (NMSC) and actinic keratosis (AK) comparing Diclofenac + DFMO with Placebo + Placebo (2 arms). Primary endpoint: Reduction of actinic keratoses at 52 weeks. Started Jan 2021; status: completed.
02
Drugs
diclofenaceflornithine
03
Conditions
non-melanoma skin cancer (NMSC)actinic keratosis (AK)
Beyond the preview
Go deeper on NCT04091022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04091022.